Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)

Next Previous
Trial Profile

Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Contezolid (Primary) ; Contezolid-acefosamil (Primary) ; Linezolid; Linezolid
  • Indications Diabetic foot
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors MicuRx Pharmaceuticals

Most Recent Events

  • 25 Feb 2025 According to Shanghai MicuRx Pharmaceutical media release , Data Monitoring Committee has completed its first safety and efficacy assessment, confirming that the drugs safety and efficacy profiles meet favorable expectations and recommending the trial proceed as planned.
  • 01 Nov 2024 Planned End Date changed from 1 Jun 2024 to 30 Jun 2026.
  • 01 Nov 2024 Planned primary completion date changed from 1 Jun 2024 to 30 Jun 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top